Session: 602. Myeloid Oncogenesis: Basic: Poster II
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Acute Myeloid Malignancies, AML, Diseases, Metabolism, Myeloid Malignancies, Biological Processes, Technology and Procedures, Omics technologies
Unexpectedly, the surviving cells had significantly higher levels of protein synthesis during maximum response to chemotherapy and BCAA restriction. We anticipated that BCAA restriction after chemotherapy would lower mTOR activity and thus protein synthesis rates. Unexpectedly, we found that ribosomal gene transcripts were enriched, and OPP incorporation in newly synthesized peptides increased in AML cells restricted for BCAAs combined with chemotherapy in vivo. Using low-input Ribo-seq to analyze paired transcriptome and translatome data, we found activated ribosomal protein translation and elevated production of the dioxygenase, 2-oxoglutarate-and-iron-dependent oxygenase 1 (OGFOD1). OGFOD1 modulates the fidelity of ribosomal codon-anticodon pairing through ribosome hydroxylation in proximity to the decoding center where this pairing takes place. Accordingly, AML cells with increased OGFOD1 in vivo had reduced ribosome stalling by ribosome profiling. Conversely, inhibiting OGFOD1 led to translation arrest, reduced protein production and improved animal survival following chemotherapy. Our data therefore suggest that OGFOD1 may enable cells to bypass BCAA shortage by permitting less stringent translation accuracy and targeting OGFOD1 and restricting amino acids can counteract this chemoresistance mechanism. Modifying translation fidelity is a previously unrecognized strategy in AML and has important potential implications across other oncologic contexts.
Disclosures: Mayerhofer: Regeneron: Current Employment. Miller: Roche: Consultancy; Foundation Medicine: Consultancy. Scadden: VCanBio: Consultancy; Sonata Therapeutics: Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees; Editas Medicine: Membership on an entity's Board of Directors or advisory committees; Agios Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Lightning Biotherapeutics: Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees; Clear Creek Bio: Current holder of stock options in a privately-held company; Garuda Therapeutics: Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees; Carisma Therapeutics: Membership on an entity's Board of Directors or advisory committees.